



Biotech Daily

Wednesday September 10, 2014

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH EVEN: LIVING CELL UP 10%
UNIVERSAL BIOSENSORS DOWN 5%**
- * **BURNET CHAIR ALASTAIR LUCAS STANDS DOWN**
- * **VICTORIA OPENS APPLICATIONS FOR FOUR \$150k FELLOWSHIPS**
- * **HUNTER HALL TAKES 10% OF ALCHEMIA**
- * **BVF PARTNERS, MARK LAMPERT TAKE 12.5% IN VIRALYTICS**
- * **MINING INVEST, ELIAS LEO KHOURI DOWN TO 9% OF BIOPROSPECT**
- * **CALZADA LOSES DIRECTOR DR ROGER ASTON TO ONCOSIL**

MARKET REPORT

The Australian stock market fell 0.6 percent on Wednesday September 10, 2014 with the S&P ASX 200 down 33.6 points to 5,574.3 points.

Twelve of the Biotech Daily Top 40 stocks were up, 12 fell, 12 traded unchanged and four were untraded.

Living Cell was the best, up 0.6 cents or 10 percent to 6.6 cents with 40,059 shares traded.

Cellmid climbed 7.7 percent; Avita was up five percent; Clinuvel, Ellex and Prana were up four percent or more; Anteo climbed 3.85 percent; Nanosonics and Prima rose more than two percent; Phosphagenics and Viralytics were up more than one percent; with Alchemia and Resmed up by less than one percent.

Universal Biosensors led the falls, down one cent or 5.3 percent to 18 cents with 61,450 shares traded.

AcruX, Bionomics and Pharmaxis lost more than three percent; Medical Developments, Neuren, Sirtex and Tissue Therapies shed two percent or more; Benitec and Cochlear fell more than one percent; with GI Dynamics, Mesoblast and Psivida down by less than one percent.

BURNET INSTITUTE

The Burnet Institute says that chair Alastair Lucas will take extended leave “after being unexpectedly diagnosed with a serious illness over the weekend”.

The Institute said that Robert Milne had been appointed acting chair.

The Institute said that Mr Lucas would take leave as chairman of the Medical Research Future Fund Action Group and chairman of investment banking at Goldman Sachs Australia.

In a media release The Burnet Institute said that Mr Lucas was also on the board of Research Australia and was the founder and chair of Cell Care Australia.

The Institute said that Mr Lucas had been the chair for the past 12 years, “guiding the Institute’s growth and success to become an internationally-renowned medical research and public health organization”.

The Burnet Institute said that Baker IDI Heart and Diabetes Institute chairman UBS Australia vice-chairman Peter Scott would become the chairman of the MRFF Action Group.

The Institute said that Mr Lucas would remain the foundation chair of the MRFF Action Group and provide strategic input.

“We look forward to his return as chair of Burnet in coming months,” the Institute said.

“Alastair’s exemplary leadership throughout the health and medical research sector has already saved and improved the lives of many people and promises to save and improve the lives of many more in the future,” the Institute said.

The Institute said that its staff, board and supporters “wish Alastair, his family and close friends well as he takes on this unexpected challenge”.

VICTORIA GOVERNMENT

Victoria’s Minister for Innovation Louise Asher says applications have opened for the \$150,000 Victorian Endowment for Science, Knowledge and Innovation fellowships.

Ms Asher said that the Victorian Endowment for Science, Knowledge and Innovation (Veski) innovation fellowships provided \$150,000 over three years against matched and in-kind funding so that researchers working overseas could relocate their research activities to Victoria.

A spokesman for Ms Asher said that four fellowships would be available in the 2014 round.

“These important fellowships are open to expatriate Australian and non-Australian researchers working in biotechnology, biomedical, advanced manufacturing, including food science and bioengineering, environmental technologies and enabling sciences,” Ms Asher said.

“Previous Veski innovation fellows have used their funding for research across a wide range of areas including medical imaging technologies, bionics, next generation semiconductors, musculoskeletal health, malaria and advanced materials,” Ms Asher said.

“Victoria’s leadership in science, technology and innovation is driven by our talented and creative researchers so it is important that we support their work and professional development,” Ms Asher said.

“Since 2011, the Victorian Coalition Government has committed over \$9 million to recognize and reward research excellence through a range of fellowships and awards,” Ms Asher said.

The Veski website said that it was in its tenth year of operation.

A media release from Ms Asher said that applications would close on November 14, 2014.

For more information go to: www.veski.org.au/vif or call +613 9635 5700.

ALCHEMIA

Hunter Hall Investment Management has increased its substantial holding in Alchemia from 29,250,521 shares (9.02%) to 32,508,583 shares (10.02%).

Hunter Hall said it acquired the shares between July 9 and September 5, 2014, with the single largest purchase on August 22 of 277,565 shares for \$167,253 or 60.3 cents a share.

Alchemia was up half a cent or 0.8 percent to 61.5 cents.

VIRALYTICS

BVF Partners and Mark Lampert say they have increased their substantial holding in Viralytics from 14,807,075 shares (8.05%) to 22,931,933 shares (12.46%).

In March, the San Francisco, California-based BVF Partners and Mr Lampert became substantial in Viralytics through participation in the company's \$27 million placement at 28 cents a share and in June increased its holding (BD: Mar 13, 14; Jun 11, 2014)

Today, BVF Partners and Mr Lampert said they acquired the 8,124,858 shares in 15 separate trades between June 11 and September 8, 2014, with the single largest acquisition on September 8, of 3,813,737 shares for \$1,029,709 or 27 cents a share.

Viralytics was up half a cent or 1.85 percent to 27.5 cents.

BIOPROSPECT

Mining Investments says it has reduced its holding in Bioprospect from 735,000,000 shares (23.16%) to 298,909,928 shares (9.42%).

In June, Mining Investments increased but was diluted in Bioprospect from 700,000,000 shares (24.15%) to 735,000,000 shares (23.16%) (BD: Jun 11, 2014).

The Newport, Victoria-based Mining Investments substantial shareholder notice was signed by director Elias Khouri.

In 2010, Elias Leo (The Gun) Khouri resigned as a director of Bioprospect citing the company's dispute with Solagran over its pine needle extract cure-all for liver disease and Alzheimer's disease (BD: Sep 17, 2010).

Earlier this week Bioprospect said it would continue acquire Invatec for its heart rate variability technology to diagnose depression and other mental illnesses and appointed former Chemgenex chief operating officer and Invion director Dr James Campbell as a director, along with several other appointments (BD: Sep 8, 2014).

Bioprospect said at that time that it proposed a 100-to-one consolidation and hoped to raise \$4 million at a post-consolidation price of 30 cents a share.

Today, the Mining Investments substantial shareholder notice said that all shares were sold or lent at 0.3 cents a share, with 36,666,667 shares sold off-market on August 27 for \$110,000; 124,423,405 shares sold on market on September 8 for \$377,694; 125,000,000 shares sold off-market "pursuant to the share sale agreement" for an unsecured loan of \$375,000; and 150,000,000 shares sold off-market for \$450,000 on September 9, 2014.

The attached share sale agreement said that Mining Investments was incorporated in the Khaimah Free Trade Zone Authority, Government of Ras Al Khaimah, with an address care of BDO Chartered Accountants and Business Advisers in Dubai, United Arab Emirates.

All details of the purchaser of the shares through the loan agreement were blacked out, except that it appears to have an 'ACN' or Australian Company Number.

Bioprospect was unchanged at 0.4 cents with 5.2 million shares traded.

CALZADA

Calzada says that Dr Roger Aston has tendered his resignation as non-executive director, effective immediately.

Calzada said that Dr Aston had resigned “due to his current executive positions and his recent appointment as chairman of Oncosil Medical ... [and] he no longer has the necessary time to add value as a director of Calzada” (BD: Sep 9, 2014).

Dr Aston said he was “disappointed to be stepping down at this exciting time in Calzada’s evolution”.

The company said that Dr Aston had been a Calzada director since November 15 2013.

Calzada fell 0.1 cents or one percent to 9.6 cents.